Therapeutic Effect of Sunitinib Malate and Its Influence on Blood Glucose Concentrations in a Patient with Metastatic Insulinoma
Abstract
Standard cytotoxic chemotherapy has limited efficacy in advanced insulinomas, and control of blood glucose concentrations in these patients may be difficult. This article describes an elderly (74-year-old) man with metastatic insulinoma and severe hypoglycemia who was treated with repeated 6-week cycles of oral sunitinib malate (25 mg/day for 4 weeks, followed by 2 weeks off treatment). After treatment for more than 2 years, his condition improved and he continued to have a good quality of life with no evidence of tumor progression based on PET/CT findings. Although sunitinib treatment lowered the patient's blood glucose concentrations further and induced repeated symptomatic hypoglycemic episodes, he was able to tolerate the treatment well after changing the timing of sunitinib dosing and adjusting his diet.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Sunitinib stabilized tumor growth after two years of treatment but worsened hypoglycemia, an effect attributed to enhanced glucose-dependent insulin secretion and reduced insulin clearance.
“In one published by Chen and colleagues, sunitinib stabilized tumor growth after two years of treatment but was noted to worsen hypoglycemia, an effect attributed to the drug's ability to enhance glucosedependent insulin secretion and reduce insulin clearance [96-98].”
From Non-Diabetic Hypoglycemia: Evaluation and Management in Adults (2025) · cites this paper as [96]
Cited by
Sorted by citations
Non-Diabetic Hypoglycemia: Evaluation and Management in Adults
Looi, E., & Lawler, H. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134393 · Cited by 10 · see citing works
“In one published by Chen and colleagues, sunitinib stabilized tumor growth after two years of treatment but was noted to worsen hypoglycemia, an effect attributed to the drug’s ability to enhance glucose-dependent insulin secretion and reduce insulin clearance [96–98].”
- Authors
- Chen, J., Wang, C., Han, J., Luan, Y., Cui, Y., Shen, R., Sha, D., Cong, L., Zhang, Z., & Wang, W.
- Affiliations
- Shandong University (CN)
- Venue
- Expert Review of Anticancer Therapy
- Publisher
- Informa UK Limited
- Published
- 2013-06
- Volume
- 13
- Issue
- 6
- Pages
- 737-743
- ISSN
- 1473-7140 (ISSN-L)
- 1744-8328
- OpenAlex
- W2128477626
- Cited by
- 37
- References
- 0
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 1 · 2022: 3 · 2021: 1 · 2020: 1 · 2019: 5 · 2018: 6 · 2017: 4 · 2016: 5 · 2014: 3 · 2013: 2
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Review of Anticancer Therapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- sunitinib malate, metastatic insulinoma, hypoglycemia, glycemic control, tyrosine kinase inhibitors, timing of drug administration, dietary change, elderly patients, quality of life
- MeSH terms
- Sunitinib, Aged, Antineoplastic Agents, Blood Glucose, Humans, Indoles, Insulinoma, Liver Neoplasms, Male, Pyrroles, Tomography, Emission-Computed, Fluorodeoxyglucose F18, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
